LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
OGEN
Oragenics, Inc.
There isn't enough reported data to score OGEN yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
OGEN Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Unavailable | |
| Unavailable |
OGEN's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
OGEN PE Valuation
OGEN has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
OGEN Forward outlook
There aren't enough analyst estimates for OGEN to show an outlook.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the stronger earnings trend. Trailing diluted EPS is up 51% for LLY versus OGEN down 111%.
OGEN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$24.05 | +$185.95 |
| Q2 2025 | -$33.49 | +$190.61 |
| Q1 2025 | -$45.69 | +$208.41 |
| Q4 2024 | -$63.09 | +$212.31 |
| Q3 2024 | -$210.00 | -$63.49 |
| Q2 2024 | -$224.10 | -$49.09 |
| Q1 2024 | -$254.10 | -$70.39 |
| Q4 2023 | -$275.40 | -$61.99 |
OGEN is still losing money, but far less than before: $24.05 per share over the past year, against $918.00 at its worst in mid-2020.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
OGEN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2023 | $7.5K | -91% |
| Q2 2023 | $13.2K | -57% |
| Q1 2023 | $17K | +13% |
OGEN's revenue has slid since its 2022 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2023 | -28053% | -23514 points |
| Q2 2023 | -23622% | -11763 points |
| Q1 2023 | -17063% | +13502 points |
| Q3 2022 | -4539% | N/A |
| Q2 2022 | -11859% | N/A |
| Q1 2022 | -30565% | N/A |
OGEN's operating margin was −28053% last quarter, down 16194 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over OGEN on cash generation, producing positive trailing cash flow while its opponent burns cash.
OGEN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2M | +$951.1K |
| Q2 2026 | -$2.2M | -$872.4K |
| Q1 2026 | -$2.2M | -$88.6K |
| Q4 2025 | -$2.8M | -$817.1K |
| Q3 2025 | -$3M | -$1M |
| Q2 2025 | -$1.3M | +$230.2K |
| Q1 2025 | -$2.1M | +$952.2K |
| Q4 2022 | -$2.4M | -$532.1K |
OGEN has burned cash in almost every quarter: −$9M over the past year, against −$8M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over OGEN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
OGEN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.9% | +83.4K shares |
| 1 year | +517% | +3.8M shares |
| 3 years | +6585% | +4.4M shares |
| 5 years | +7787% | +4.5M shares |
| Available history | +19107% | +4.5M shares |
OGEN has 5M diluted shares, up 517% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
OGEN Net Leverage
OGEN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
OGEN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 25.9 | Oversold |
| Stochastic | 5.7 | Oversold |
OGEN's weekly RSI is 26 (oversold) and its Stochastic is 6 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
OGEN PE vs Healthcare Sector
OGEN has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over OGEN on trend strength, trading above more of its moving averages.
OGEN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.42 | 17% below |
| 20 week MA | $0.48 | 27% below |
| 50 week MA | $0.63 | 44% below |
| 100 week MA | $2.60 | 87% below |
| 200 week MA | $41.7 | 99% below |
OGEN is in a downtrend: it's below all five of its weekly moving averages, and 99% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over OGEN on returns for 2026, with the stronger performance.
OGEN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $948.6 | $774.0 | -18% |
| 2021 | $774.0 | $867.8 | +12% |
| 2022 | $867.8 | $261.0 | -70% |
| 2023 | $261.0 | $168.9 | -35% |
| 2024 | $168.9 | $13.6 | -92% |
| 2025 | $13.6 | $0.86 | -94% |
| 2026 YTD | $0.86 | $0.35 | -59% |
OGEN has finished four years in a row lower, and it's down 59% so far in 2026.